TW we were talking about what Lytle should sell to the panel.
Tarvacin is going into the clinic treating cancer with oodles of promising pre-clinical data in various solid tumors vs. an anti-viral IND in the future, the company is still working on 'proof of concept' issues and has one guinea pig model to talk about.
The anti-viral IND approval/enrollment is at least a year away, enrollment for cancer is now. Tarvacin + Chemo is the DEAL to talk about....the flippin' FDA and oncologists just love to enhance chemo, and Tarvacin can do just that...Taxotere and Gemzar...
Sure he can link anti-viral potential to Tarvacin, but that shouldn't be the entire focal point of his discussion...
I didn't say viral indications were slow to develop. Anti-viral is still in early stage development vs. the oncology side....that's all.
katie....
News 
Market Data 
Discover 
AI
